Innovation of new diagnostic modalities for pancreatic cancer using PET-MRI

Innovation of new diagnostic modalities for pancreatic cancer using PET-MRI - PET-MRI for diagnosis of pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016679

Enrollment

Registered

2015-03-02

Start date

2015-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Conventional PET-CT and ERCP are compared to PET-MRI and fluorescent pancreatography.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)performance status:0-2 2)without dimentia or psychiatric disorder 3)T. Bil=<5.0 mg/dl, AST=<200 IU/L, ALT=<200 IU/L, serum creatinine=<1.5mg/dl 4)without acute pancreatitis 5)patients who agree this study on document of informed consent

Exclusion criteria

Exclusion criteria: 1:Patients with contraindication for pilocarpine hydrochloride, such as severe ischemic heart disease, bronchial asthma, ileus, obstruction of urinary tract, epilepsy, Parkinsonism and Parkinson disease, iritis 2:Patients with allegy for indocyanine green

Design outcomes

Primary

Measure	Time frame
Efficacy of PET-MRI for diagnosis of pancreatic cancer compared to PET-CT	—

Secondary

Measure	Time frame
1)Efficay of elastography and indocyanine green fluorescent pancreatography for diagnosis of pancreatic cancer 2)incidence of pancreatic fistula	—

Countries

Japan

Contacts

Public ContactTatsuo Shimura

Fukushima Medical University Department of Organ Regulatory Surgery

tshimura@fmu.ac.jp+81-24-547-1259

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026